| Trends in the use of drug therapies in patients with acute myocardial infarction: 1988 to 1992. | |
| | |
MedLine Citation:
|
PMID: 7908298 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: In this study, we investigated the use of thrombolytic agents and other cardiac drugs in a national cohort of patients with acute myocardial infarction and assessed the influence of large clinical studies on types of thrombolytic therapy prescribed. BACKGROUND: Information about usage patterns for these drugs is unavailable, and little is known about the impact of large clinical trials on their use. METHODS: We conducted a retrospective cohort study of 65,011 patients who were treated for acute myocardial infarction during fiscal years 1988 to 1992 (October 1, 1987 to September 30, 1992) in hospitals participating in the SMS Corporation's on-line data pool. RESULTS: The overall thrombolysis rate for patients with acute myocardial infarction increased from 11% in fiscal year 1988 to 18% in fiscal year 1990 and has remained approximately at that level since then. In mid-1989, tissue plasminogen activator was used in 90% of the patients receiving thrombolysis, whereas streptokinase was used in only 10%. Since 1991, tissue plasminogen activator has been used in 60% of patients and streptokinase in almost 30%. Much of this change came after presentation and publication of results of the Second Gruppo Italiano per lo Studio Della Sopravvivenza nell'Infarto Miocardico (GISSI-2) and the Third International Study of Infarct Survival (ISIS-3) trials. Over these 5 years, use of beta-adrenergic blocking agents increased steadily, and use of calcium-channel blocking agents declined steadily. CONCLUSIONS: Current usage rates of thrombolytic therapy are lower than expected, but trends in usage rates for beta-blockers and calcium channel blockers reflect their increasing and decreasing approval, respectively. Presentation and publication of results from the Third International Study of Infarct Survival and the Second Gruppo Italiano per lo Studio Della Sopravvivenza nell'Infarto Miocardico trials appear to have influenced the type of thrombolytic agent prescribed. |
| | |
Authors:
|
C L Pashos; S L Normand; J B Garfinkle; J P Newhouse; A M Epstein; B J McNeil |
Related Documents
:
|
18020578 - Recombinant plasminogen activators: a comparative review of the clinical pharmacology a... 11719118 - Thrombolytic treatment of acute myocardial infarction after out-of-hospital cardiac arr... 3297008 - Thrombolysis and stroke. past and future. 11213858 - A review of available fibrin-specific thrombolytic agents used in acute myocardial infa... 20711038 - Coming of age: coronary computed tomography angiography. 6627688 - Serum creatine kinase in obese subjects before and during weight reduction. |
Publication Detail:
|
Type: Journal Article; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Journal of the American College of Cardiology Volume: 23 ISSN: 0735-1097 ISO Abbreviation: J. Am. Coll. Cardiol. Publication Date: 1994 Apr |
Date Detail:
|
Created Date: 1994-05-05 Completed Date: 1994-05-05 Revised Date: 2010-03-24 |
Medline Journal Info:
|
Nlm Unique ID: 8301365 Medline TA: J Am Coll Cardiol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1023-30 Citation Subset: AIM; IM |
Affiliation:
|
Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts 02115. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Antagonists
/
therapeutic use Aged Aged, 80 and over Calcium Channel Blockers / therapeutic use Cohort Studies Female Humans Logistic Models Male Middle Aged Myocardial Infarction / drug therapy* Retrospective Studies Streptokinase / therapeutic use Thrombolytic Therapy / trends* Tissue Plasminogen Activator / therapeutic use |
| Grant Support | |
ID/Acronym/Agency:
|
R01-HS06341/HS/AHRQ HHS |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists; 0/Calcium Channel Blockers; EC 3.4.-/Streptokinase; EC 3.4.21.68/Tissue Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Treatment dilemmas in HIV infection.
Next Document: Cotton wool spots in AIDS: a review.